相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Michael A. Nauck
DIABETES CARE (2013)
Interpreting Adverse Signals in Diabetes Drug Development Programs
Clifford J. Bailey
DIABETES CARE (2013)
Do GLP-1-Based Therapies Increase Cancer Risk?
Michael A. Nauck et al.
DIABETES CARE (2013)
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Peter C. Butler et al.
DIABETES CARE (2013)
An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology
Evis Harja et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2013)
Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Craig J. Currie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model
Belinda Gier et al.
DIABETES (2012)
The Human GLP-1 Analog Liraglutide and the Pancreas Evidence for the Absence of Structural Pancreatic Changes in Three Species
Niels C. B. Nyborg et al.
DIABETES (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Clinical Implications of the ACCORD Trial
S. Genuth et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Faramarz Ismail-Beigi et al.
ANNALS OF INTERNAL MEDICINE (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
The Safety of Incretin-Based Therapies-Review of the Scientific Evidence
Daniel J. Drucker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Richard M. Bergenstal et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
Krystyna Tatarkiewicz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Diabetes and Cancer A consensus report
Edward Giovannucci et al.
DIABETES CARE (2010)
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
J. S. Nachnani et al.
DIABETOLOGIA (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Insulin analogues and cancer risk: cause for concern or cause celebre?
M. Pollak et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?
Hertzel C. Gerstein
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus
Zeina A. Habib et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bone Loss and Fracture Risk Associated with Thiazolidinedione Therapy
Daniel M. Riche et al.
PHARMACOTHERAPY (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
Jacqueline A. Koehler et al.
DIABETES (2009)
Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes Interactions With Metformin
Aleksey V. Matveyenko et al.
DIABETES (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Does diabetes therapy influence the risk of cancer?
U. Smith et al.
DIABETOLOGIA (2009)
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
J. M. Jonasson et al.
DIABETOLOGIA (2009)
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
H. M. Colhoun
DIABETOLOGIA (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie et al.
DIABETOLOGIA (2009)
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
L. G. Hemkens et al.
DIABETOLOGIA (2009)
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
David M. Kendall et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
